ASCO2021: Precision medicine promotes the progress of gastrointestinal cancer treatment

The molecular atlas in the field of gastrointestinal (GI) cancer is the best precision medicine

Everyone in the GI field is very pleased to see that ASCO has identified the molecular map of GI cancer as an annual progress in 2021, because it illustrates the tremendous achievements of this field in precision medicine and targeted therapy for patients

Combined immunotherapy produces a lasting response in liver cancer

Immune checkpoint inhibitors have paved the way for exponential gains in the field of GI and further immuno-oncology

In similar circumstances, CheckMate-040's long-term follow-up data brings hope to patients with advanced HCC

Rachna T.

The future development direction of the GI field

These and other recent advances in the GI field highlight the potential of next-generation sequencing, molecular analysis, and biomarker detection to expand patient treatment options

For example, circulating tumor DNA (ctDNA) detection can detect cancer cells in the blood earlier than traditional imaging and provide personalized treatment recommendations for gastrointestinal cancers

Original source

1. Finn RS, Qin S, Ikeda M, et al.
   Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
   N Engl J Med .
   2020;382:1894-1905.
   
2. Finn RS, Qin S, Ikeda M, et al.
   IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
   J Clin Oncol .
   2021;39(suppl;abstr 267).
   
3. El-Khoueiry A, Yau T, Kang YK, et al.
   Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
     J Clin Oncol .
   2021;39(suppl;abstr 269).